First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $3.2B — +9.0% growth in a single year.
What Moves the Stock
1ExcelsiusGPS robotic system placements and utilization rates (installed base approaching 200+ units, targeting 20-30% annual growth)
2NuVasive integration progress and synergy realization (cost synergies, sales force productivity, product portfolio rationalization)
3US spine market procedure volumes, particularly elective spine surgeries which drive 70%+ of revenue and correlate with employment levels and commercial insurance coverage
4New product launches and FDA approvals (expandable interbody devices, AI-enabled surgical planning software, next-generation robotics)
5Market share gains in enabling technologies versus Medtronic Mazor, Stryker Mako Spine, and Zimmer Biomet Rosa platforms
growth - The stock attracts growth-oriented investors focused on the enabling technologies platform (robotics, navigation…
Rising interest rates have modest negative impact through two channels: (1) Hospital capital budgets tighten as borrowing costs increase…
Watch on earnings: US elective surgery volumes and hospital admission rates (correlation with employment levels and commercial insurance coverage), Medicare physician fee schedule updates and proposed reimbursement changes for spine procedures (CPT codes 22630, 22633, 22853), ExcelsiusGPS installed base growth and quarterly utilization rates (procedures per system).
One Sentence Summary:
Globus Medical: the story is balanced — excelsiusgps robotic system placements and utilization rates (installed base approaching 200+ units, targeting 20-30% annual growth).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.